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The brief description of tumors being “wounds that do not heal”
by Dr. Harold F. Dworak nearly three decades ago (N Engl J Med,
1986) (1) has provided not only a vivid illustration of neoplastic
diseases in general but also, in retrospect conceptually, a plausi-
ble immunological definition of cancers. Based on our current
understanding in the field, it could have even a multi-dimensional
meaning attached with. This relates to several important issues,
which need to be addressed further, i.e., in terms of a close
link between chronic inflammation and tumorigenesis widely
observed; clinical and experimental evidence of immunity against
tumors versus the highly immunosuppressive tumor microenvi-
ronment being associated; and their underlying immunological
mechanisms, oncogenic basis, as well as the true causal relationship
in question (2–5).
Recent findings from studies into the pathogenesis of autoim-
munity and, more importantly, the mechanisms, which protect
against it, have offered some new insights for our understanding in
this direction. Chronic or persistent autoimmune-like inflamma-
tory conditions are evidently associated with tumor development.
The important question is about their true causal relationship.
Chronic or persistent inflammation has been shown to contribute
directly to tumor development by triggering neoplastic transfor-
mation and production of inflammatory mediators, which could
promote cancer cell survival, proliferation, and invasion (2, 3). On
the other hand, tumors are mutated self-tissue cells to which the
host immune system is largely tolerized otherwise. Although the
mutations may give rise to the expression of tumor-specific anti-
gens (TSA) or tumor-associated antigens (TAA), most of these
TSAs/TAAs are found to be poor immunogens (6). The ongoing
inflammatory conditions may therefore reflect a desperate attempt
of the host immune system to mount anti-tumor responses,
though ineffectively, being a consequence of the continuous yet
largely futile triggering by those poorly immunogenic TSAs/TAAs.
Furthermore, during autoimmune or overtly persistent immuno-
logical responses, many regulatory mechanisms are triggered in
the host in attempts to limit the ongoing harmful inflammatory
reactions. Such a negative feedback regulation is known to be
crucial in preventing normal individuals from immune-mediated
diseases (7). As a result of the negative feedback loop, however, an
excessive production of anti-inflammatory or immunosuppressive
molecules followed by the exhaustion of the immune effector
cells may instead lower the ability of the host immune system
to mount specific anti-tumor responses, allowing the escape of
tumor or mutated cells from immunosurveillance. This may also
help to explain why the most effective way to enhance host immu-
nity against cancer is by targeting the negative arm of immune
regulation (8–10).
In this Frontiers Research Topic, we have gathered current
views and cutting-edge findings from many experts in these inher-
ent overlapping fields of oncology, autoimmunity, and tumor
immunology. It compiles a total of 15 articles in different for-
mats, of concise but informative Mini-review/Reviews, Orig-
inal Research Articles with novel experimental findings, and
some very thought-provoking new Hypothesis/Theory/Opinion/
Perspectives. These are now made freely available to our potential
readership who may be particularly interested in this cutting-edge
area, covering three key issues as outlined below:
• Cancers, Inflammation, and the causal relationship;
• Immune effector and regulatory mechanisms involved in
autoimmuno-anti-tumor immunity (AATI);
• Guiding the misguided: AATI alternatively switched on for
effective cancer treatment.
For the highly cross-disciplinary nature of this Research Topic,
however, the above are reflected in different ways in these arti-
cles, crossing throughout the topic. It starts by outlining evi-
dence of the host immune system that may naturally protect
against cancers, while it could also cause autoimmunity – being
an evolutionally acceptable “side effect” (Chapters 1–2); followed
by explaining how autoimmunity could be a “Double-Agent”
involved in both tumor-killing and cancer promotion linked to
inflammation (Chapters 3–5). It addresses further by dissect-
ing the detailed cellular and molecular mechanisms potentially
involved in these processes (Chapters 6–10). These together may
help to provide a good basis for the development of novel thera-
peutic approaches, including stem cell-based immunotherapy, for
future cancer treatment (Chapters 11–15). By understanding how
the immune system is normally regulated, why dysregulation of
which may cause the immunological–oncological related diseases,
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we aim and hope that the contents of this Research Topic can also
trigger further active discussions among scientists in the fields, as
to how the so-called “self-reactivity” (autoimmune responses) can
be alternatively switched on and redirected, immunologically or
molecularly, for effective cancer treatment.
Finally, I would like to thank all the authors for their valu-
able contributions to this Research Topic, and to express my great
appreciations to many members of the journal editorial team,
especially Ms. Rosa Mancebo and Ms. Jessica Kandlbauer, for their
professional dedication and kind help throughout the process.
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